Targeting z-Crystallin by aspirin restores the sensitivity to cisplatin in resistant A2780 ovarian cancer cells

Author:

Lulli Matteo1,Roviello Giandomenico1,Catalano Martina1,Parenti Astrid1,Molli Alice1,Napoli Cristina1,Landini Ida1,Schiavone Nicola1,Lapucci Andrea1

Affiliation:

1. University of Florence

Abstract

Abstract Purpose Ovarian cancer is the deadliest gynaecologic malignancies worldwide. Platinum based chemotherapy is the mainstay treatment for ovarian cancer; however, frequent recurrence and chemoresistance onset in patients with advanced diseases remain a therapeutic challenge. Although mechanisms underlying the development of chemoresistance are still ambiguous, the B-cell lymphoma-2 (Bcl-2) family is closely associated with chemoresistance in ovarian cancer. We previously disclosed that Zeta-Crystallin (CryZ) is a post-transcriptional regulator of Bcl-2 gene expression, by binding to bcl-2 mRNA and increasing its half-life. Here, we investigated the role of CryZ as a novel therapeutic target in ovarian carcinoma by modulating the protein activity with acetylsalicylic acid (ASA) to restore chemosensitivity.Methods Inhibition of CryZ binding activity to Bcl-2 and Bcl-xl mRNA targets by ASA was evaluated in A375 cells. Cytotoxicity assays were conducted in A2780S and A2780R ovarian cancer cells to evaluate if CryZ binding activity inhibition and CryZ silencing were able to reverse cisplatin resistance.Results ASA inhibits the binding of CryZ to Bcl-2 and Bcl-xl mRNAs. Furthermore, ASA-treatment or CryZ silencing are able to increase and restore the chemosensitivity in both sensitive and resistant A2780 ovarian cancer cell lines, respectively. ​Conclusion In this research article we demonstrated that the pharmacological or genetic inhibition of CryZ restores the sensitivity to cisplatin in a model of sensitive or resistant ovarian cancer cells. These findings suggest a new gene-targeted chemotherapeutic approach to restore the cytotoxicity in drug-resistant ovarian cancers and increase the sensitivity in non-resistant cells.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3